Fang Zhong, Li Jin, Yu Xiaoyu, Zhang Dandan, Ren Guangxu, Shi Bisheng, Wang Cong, Kosinska Anna D, Wang Sen, Zhou Xiaohui, Kozlowski Maya, Hu Yunwen, Yuan Zhenghong
Key Laboratory of Medical Molecular Virology, Shanghai Public Health Clinical Center, Shanghai Medical College of Fudan University, Shanghai 201508, People's Republic of China; Key Laboratory of Medical Molecular Virology, School of Basic Medical Sciences, Shanghai Medical College of Fudan University, Shanghai 200032, People's Republic of China; and.
Key Laboratory of Medical Molecular Virology, Shanghai Public Health Clinical Center, Shanghai Medical College of Fudan University, Shanghai 201508, People's Republic of China;
J Immunol. 2015 Nov 15;195(10):4873-83. doi: 10.4049/jimmunol.1501362. Epub 2015 Sep 28.
Chronic hepatitis B virus (HBV) infection is characterized by T cell tolerance to virus. Although inhibition of T cell responses by myeloid-derived suppressor cells (MDSCs) has been observed in patients with chronic hepatitis B (CHB), the mechanism for expansion of MDSCs remains ambiguous. In this study, a significant increased frequency of monocytic MDSCs (mMDSCs) was shown positively correlated to level of HBsAg in the patients with CHB. We further found hepatitis B surface Ag (HBsAg) efficiently promoted differentiation of mMDSCs in vitro, and monocytes in PBMCs performed as the progenitors. This required the activation of ERK/IL-6/STAT3 signaling feedback. Importantly, the mMDSCs polarized by HBsAg in vitro acquired the ability to suppress T cell activation. Additionally, treatment of all-trans retinoic acid, an MDSC-targeted drug, restored the proliferation and IFN-γ production by HBV-specific CD4(+) and CD8(+) T cells in PBMCs from patients with CHB and prevented increase of viral load in mouse model. In summary, HBsAg maintains HBV persistence and suppresses T cell responses by promoting differentiation of monocytes into mMDSCs. A therapy aimed at the abrogation of MDSCs may help to disrupt immune suppression in patients with CHB.
慢性乙型肝炎病毒(HBV)感染的特征是T细胞对病毒产生耐受。虽然在慢性乙型肝炎(CHB)患者中已观察到髓系来源的抑制细胞(MDSC)对T细胞反应的抑制作用,但MDSC扩增的机制仍不明确。在本研究中,CHB患者中单核细胞MDSC(mMDSC)的频率显著增加,且与HBsAg水平呈正相关。我们进一步发现,乙型肝炎表面抗原(HBsAg)在体外可有效促进mMDSC的分化,外周血单个核细胞(PBMC)中的单核细胞作为其祖细胞。这需要激活ERK/IL-6/STAT3信号反馈。重要的是,体外由HBsAg极化的mMDSC获得了抑制T细胞活化的能力。此外,使用MDSC靶向药物全反式维甲酸治疗,可恢复CHB患者PBMC中HBV特异性CD4(+)和CD8(+) T细胞的增殖及IFN-γ产生,并防止小鼠模型中病毒载量增加。总之,HBsAg通过促进单核细胞分化为mMDSC来维持HBV持续感染并抑制T细胞反应。针对消除MDSC的治疗可能有助于打破CHB患者的免疫抑制。